aTyr Pharma
ATYR
111 hedge funds and large institutions have $43.7M invested in aTyr Pharma in 2026 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 27 increasing their positions, 30 reducing their positions, and 8 closing their positions.
350% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 8
174% more call options, than puts
Call options by funds: $766K | Put options by funds: $280K
32% more funds holding
Funds holding: 84 → 111 (+27)
1.21% more ownership
Funds ownership: 55.96% → 57.17% (+1.2%)
10% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 30
22% less capital invested
Capital invested by funds: $55.7M → $43.7M (-$12M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.89M |
| 2 |
Millennium Management
New York
|
+$1.39M |
| 3 |
Two Sigma Investments
New York
|
+$583K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$149K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$13.6M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$799K |
| 3 |
TM
Tikvah Management
Charlotte,
North Carolina
|
-$361K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$231K |
| 5 |
Morgan Stanley
New York
|
-$150K |
ATYR Hedge Fund Activity: Q1 2026 in Review
111 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2026, worth a combined $43.7M — down 22% from $55.7M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ATYR positions and 8 closed out — a net gain of 28 holders — while 27 added to existing stakes and 30 trimmed.
The largest buyer was UBS Group, adding an estimated $1.89M. The largest seller was Rosalind Advisors, exiting entirely with an estimated $13.6M sold.
- 111 institutional investors held aTyr Pharma (ATYR) as of Q1 2026, up from 84 in Q4 2025.
- Funds reported $43.7M of aTyr Pharma stock for Q1 2026, down 22% quarter-over-quarter.
- 36 funds opened new aTyr Pharma positions in Q1 2026 and 8 closed out, a net change of +28 holders.
- The largest aTyr Pharma buyer in Q1 2026 was UBS Group, an estimated $1.89M added.
- The largest aTyr Pharma seller in Q1 2026 was Rosalind Advisors, an estimated $13.6M sold.
Based on aggregated 13F filings for Q1 2026.